These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11107555)

  • 1. [Percutaneous transluminal septal myocardial ablation combined with permanent dual-chamber pacing in hypertrophic obstructive cardiomyopathy: a case report].
    Ochiai N; Furukawa K; Ebizawa T; Yagi T; Akashi K; Azuma A; Nakagawa M
    J Cardiol; 2000 Nov; 36(5):331-6. PubMed ID: 11107555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular endocardial pacing predicts the reduction of left ventricular outflow tract pressure gradient immediately after percutaneous transseptal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy refractory to medication.
    Chen SL; Dai ZL; Li ZQ; Hu ZY; Ye F; Zhang JJ; Zhang FF; Luo J; Zhu ZS; Lin S; Wu CQ; Tian NL
    Chin Med J (Engl); 2007 Apr; 120(7):562-8. PubMed ID: 17442203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Repeated percutaneous transluminal septal myocardial ablation leads to reduction of left ventricular outflow-tract pressure gradient in hypertrophic obstructive cardiomyopathy: a case report].
    Takeda M; Mori T; Ohashi Y; Ichikawa S; Terashima M; Ejiri J; Awano K
    J Cardiol; 2006 Jun; 47(6):313-21. PubMed ID: 16800375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy.
    Airoldi F; Di Mario C; Catanoso A; Dharmadhikari A; Tzifos V; Anzuini A; Carlino M; Briguori C; Montorfano M; Vaghetti M; Tolaro S; Colombo A
    Ital Heart J; 2000 Mar; 1(3):200-6. PubMed ID: 10806987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
    Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
    Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous transluminal septal myocardial ablation: a novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy.
    Kar S; Makkar R
    Rev Cardiovasc Med; 2001; 2(2):97-102. PubMed ID: 12439386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy.
    Pedone C; Vijayakumar M; Ligthart JM; Valgimigli M; Biagini E; De Jong N; Serruys PW; Ten Cate FJ
    Int J Cardiovasc Intervent; 2005; 7(3):134-7. PubMed ID: 16243734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy--results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing].
    Krejcí J; Groch L; Meluzín J; Vykypel T; Halámek J; Vitovec J
    Vnitr Lek; 2006 Apr; 52(4):313-20. PubMed ID: 16755987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyopathy.
    Lucon A; Palud L; Pavin D; Donal E; Behar N; Leclercq C; Mabo P; Daubert JC
    Arch Cardiovasc Dis; 2013; 106(6-7):373-81. PubMed ID: 23806305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Percutaneous transluminal septal ablation with ethanol in hypertrophic obstructive cardiomyopathy: a case report].
    Sakakibara M; Abe S; Fusegawa Y; Nakajima T; Iwata O; Goto S; Shiina Y; Handa S
    J Cardiol; 1999 Jul; 34(1):35-40. PubMed ID: 10422624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of biventricular pacing on left ventricular outflow tract pressure gradient in a patient with hypertrophic cardiomyopathy and normal interventricular conduction.
    Komsuoglu B; Vural A; Agacdiken A; Ural D
    J Cardiovasc Electrophysiol; 2006 Feb; 17(2):207-9. PubMed ID: 16533259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful percutaneous transluminal septal myocardial ablation through a right superior septal artery for a patient with hypertrophic obstructive cardiomyopathy.
    Kurita T; Tsuchikane E; Tanaka N; Suzuki T
    Cardiovasc Interv Ther; 2015 Oct; 30(4):377-81. PubMed ID: 25502014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy].
    Qiao SB; Gao RL; You SJ; Yuan JS; Chen JL; Yang YJ
    Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):210-2. PubMed ID: 16624154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy.
    Guo HC; Li JH; Jiang TY; Ren CW; Dai J; Zhou YJ; Lai YQ
    Chin Med J (Engl); 2018 Mar; 131(5):527-531. PubMed ID: 29483385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes.
    Gross CM; Schulz-Menger J; Krämer J; Siegel I; Pilz B; Waigand J; Friedrich MG; Uhlich F; Dietz R
    J Endovasc Ther; 2004 Dec; 11(6):705-11. PubMed ID: 15615561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. A new therapeutic option].
    Mogensen J; Egeblad H; Hansen PS; Jensen HK; Thuesen L
    Ugeskr Laeger; 2000 Mar; 162(10):1371-5. PubMed ID: 10745674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transcoronary ablation of septal hypertrophy versus dual-chamber cardiac pacing for the treatment of aged patients with hypertrophic obstructive cardiomyopathy].
    Gao YC; Li Y; Han ZH; Zhang XL; Zhao H; Jiang TY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Apr; 35(4):333-6. PubMed ID: 17711659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypertrophic obstructive cardiomyopathy and double-chamber pacing. Long-term results in a consecutive series of 22 patients].
    Lellouche D; Nourredine M; Duval AM; Pujadas P; Gartenlaub O; Castaigne A; Cachin JC; Guéret P
    Arch Mal Coeur Vaiss; 1999 Dec; 92(12):1737-44. PubMed ID: 10665326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dual-chamber pacing with nonsurgical septal reduction effect in patients with hypertrophic obstructive cardiomyopathy.
    Dimitrow PP; Podolec P; Grodecki J; Płazak W; Dudek D; Pieniazek P; Bacior B; Legutko J; Olszowska M; Kostkiewicz M; Kawecka-Jaszcz K; Tracz W; Dubiel JS
    Int J Cardiol; 2004 Mar; 94(1):31-4. PubMed ID: 14996471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Percutaneous transluminal septal myocardial ablation: early results and long-term follow-up].
    Tekieli Ł; Pieniazek P; Podolec P; Tomkiewicz-Pajak L; Płazak W; Musiałek P; Leśniak-Sobelga A; Przewłocki T; Biernacka B; Zmudka K; Tracz W
    Przegl Lek; 2006; 63(8):628-32. PubMed ID: 17441371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.